Antimicrobial selection
Daptomycin: bloodstream activity does not make it a pneumonia drug
An antibiotic can be useful for a bloodstream infection and unsuitable for a lung infection. Daptomycin selection and muscle-toxicity monitoring are separate checks; neither can be answered by recognizing a susceptible organism alone.
Sources checked October 12, 2026. Independent educational content, not NABP exam questions or individual treatment advice.
Keep the infection site attached to the choice
The label explicitly says daptomycin is not indicated for treatment of pneumonia. Its labeled uses include certain skin infections and Staphylococcus aureus bloodstream infections, including right-sided infective endocarditis in adults. Those uses do not establish a pneumonia regimen.
A susceptible organism is necessary information but not the entire selection decision. If a case includes both bacteremia and a suspected pulmonary source, the team must assess all infection sites rather than assuming one drug covers every site named.
Monitor muscle symptoms and CPK together
Monitor for muscle pain or weakness, particularly in the distal extremities. The label calls for weekly creatine phosphokinase (CPK) measurements and more frequent monitoring with recent or concurrent HMG-CoA reductase inhibitor use or CPK increases.
Adults with renal impairment need renal function and CPK monitored more frequently than weekly. A normal baseline CPK does not remove the need for follow-up or investigation of new symptoms.
Read the symptom-specific discontinuation thresholds
The label directs discontinuation for unexplained myopathy symptoms with CPK above 1,000 U/L, approximately five times the upper limit of normal. Without reported symptoms, it uses marked elevations above 2,000 U/L, at least ten times the upper limit.
The two thresholds belong to different clinical contexts. Do not use the asymptomatic threshold to justify continuing treatment in someone with muscle symptoms and a CPK of 1,300. Clinical review also needs alternative causes and an infection-treatment plan.
Do not make every statin combination a contraindication
Consider temporarily suspending agents associated with rhabdomyolysis, such as statins, during daptomycin treatment. The wording is a consideration and monitoring issue, not a blanket statement that every combination is formally contraindicated.
An exam answer should distinguish a site-of-infection limitation, a monitoring requirement and a toxicity-management threshold. A real treatment change requires the clinical team to weigh the infection and the muscle findings together.
A worked case
A patient receiving daptomycin and a statin develops unexplained muscle pain and CPK 1,300 U/L. A proposal waits until CPK exceeds 2,000 because that is the number remembered from the label. What distinction was missed?
- The lower threshold applies when unexplained myopathy symptoms are present.
- The 2,000 threshold refers to marked elevation without reported symptoms.
- The label directs discontinuation in the symptomatic situation above 1,000, with clinical treatment review.
Answer: The asymptomatic threshold cannot be used to dismiss the symptomatic case. Reassess treatment and the statin exposure promptly.
Try it before reading the answer
Write the key fact, decision and safety check first. These are original practice exercises, not recalled exam items.
1. Is daptomycin indicated for pneumonia?
No.
2. Is weekly CPK sufficient in adult renal impairment?
The label calls for more frequent renal and CPK monitoring.
3. Which threshold applies to unexplained symptoms with CPK 1,300?
The symptomatic threshold above 1,000 U/L.
Continue learning
Put the topic into a study planSources and scope
Source dates and limits matter. Follow the current official source for clinical or regulatory decisions. Examples are simplified teaching cases, not prescribing, diagnostic or compounding instructions. Check the full current guidance and individual clinical context.